Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies. - Savarirayan R; De Bergua JM; Arundel P; McDevitt H; Cormier-Daire V; Saraff V; Skae M; Delgado B; Leiva-Gea A; Santos-Simarro F; Salles JP; Nicolino M; et al. (Therapeutic advances in musculoskeletal disease, 2022)